Hormone medicines
Tadalafil
A PDE5 inhibitor with human evidence for erectile dysfunction; a stronger pump is not proof of muscle growth or cardiovascular protection.
Multiple randomized erectile-dysfunction trials
Practical use
Applying the explained evidence
- Where it fits
- A PDE5 inhibitor with human evidence for erectile dysfunction; a stronger pump is not proof of muscle growth or cardiovascular protection.
- Put the information into practice
- Clinical success means the endpoint measured: erections, intercourse attempts or urinary symptoms. None is a validated proxy for retained muscle, safe blood pressure during drug use or prevention of steroid-related cardiovascular injury.
- Diagnosis before a number
- Write down the symptoms, the reason a test was ordered, and the medicines already used. An isolated hormone result is a question to interpret, not a stand-alone reason to add another medicine.
- Keep this limit in view
- The cited studies assess erectile function over 12 weeks; they do not test cardiovascular prevention during nonmedical androgen exposure.
Overview
Tadalafil slows breakdown of cGMP through PDE5 inhibition. Cialis is approved in the US for erectile dysfunction and symptoms of benign prostatic hyperplasia. Erectile response still depends on sexual stimulation; this mechanism does not establish an anabolic effect.
Risks and limitations
Nitrates and riociguat are contraindicated. Alpha-blockers, antihypertensives and substantial alcohol can add to blood-pressure lowering; strong CYP3A4 inhibitors change exposure. Headache, indigestion, back pain and muscle aches occur. An erection lasting over four hours, sudden sensory loss or chest pain needs urgent care.
How to read this
Clinical success means the endpoint measured: erections, intercourse attempts or urinary symptoms. None is a validated proxy for retained muscle, safe blood pressure during drug use or prevention of steroid-related cardiovascular injury.
Research explained
Pooled on-demand ED trials
Who was studied
1,112 men, mean age 59; five randomized placebo-controlled trials lasting 12-weeks.
- Reported improved erections: active arm
- 81 %
- Reported improved erections: placebo
- 35 %
What was found
In the highest studied arm, 81% reported improved erections versus 35% with placebo; 75% of intercourse attempts were completed successfully. The erectile-function score improved 7.9 points from baseline.
What it cannot establish
Different measures have different denominators. These are ED outcomes in treated patients, not a comparison of tadalafil with other PDE5 inhibitors or an exercise-performance study.
Read the original studyDaily-treatment analysis across patient groups
Who was studied
1,913 men from six randomized placebo-controlled studies; 12-weeks.
What was found
Among severe baseline ED patients in the higher studied daily-treatment arm, 44.5% achieved the severity-specific clinically important improvement versus 11.6% with placebo.
What it cannot establish
Pooled subgroup analyses are descriptive; subgroup response patterns require confirmation and do not determine an individual regimen.
Read the original studyDuration is not a continuous effect guarantee
The label reports a mean terminal half-life around 17.5 hours in healthy people. This explains prolonged exposure, not an erection of that duration or a safe interval for interacting medicines.
Supporting sourceRead the numerator and denominator
An 81% patient response and 75% successful attempts are not interchangeable. One is the proportion of people reporting improvement; the other counts encounters, with multiple observations possible for one person.
Supporting sourceDrug interactions outlast a workout
Continuous exposure can matter even when the desired effect is no longer noticed. Tell emergency clinicians about PDE5-inhibitor use; do not self-treat associated chest pain with nitrates.
Supporting sourceWhat has not been demonstrated here
Neither pooled analysis measures muscle hypertrophy, androgen-related heart remodeling or a safe combination with performance drugs. Vascular mechanism alone cannot supply those missing outcome data.
Supporting sourceComparisons require comparable trials
The severe-ED subgroup uses a specific score-change threshold. It cannot be directly ranked against a different drug’s percentage of successful intercourse attempts.
Supporting sourceClaims versus findings
Not established
Tadalafil protects against the cardiovascular risks of a cycle.
The cited studies assess erectile function over 12 weeks; they do not test cardiovascular prevention during nonmedical androgen exposure.
Check the evidenceCommon questions
Is it interchangeable with sildenafil?
Both inhibit PDE5, but their exposure profiles, product indications and interaction considerations differ. Separate placebo-controlled trials are not a head-to-head ranking.
SourceSources
Cialis prescribing information
Five-trial integrated analysis
Six-trial daily-treatment analysis
Sources checked 2026-09-28.
General education; not a personal treatment plan.